SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sultan who wrote (14639)12/14/2004 12:22:50 PM
From: semi_infinite   Read Replies (2) of 52153
 
OT QLT - Debated to either buy the call or stock and decided to joined you guys at 14.91-95. Lots of lottery tickets (Dec 45 calls) being bought on EYET and a few puts on QLT. Huge premiums on EYET and hardly any on QLT. Merill Lynch analyst thinks Macugen will do well because ret specialists will make more money with it than Visudyne. That must be the consensus view with the way EYET is priced.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News